Background Edoxaban is an oral, once‐daily, direct factor Xa inhibitor under investigation
for stroke prevention in patients with atrial fibrillation and for treatment and secondary …

This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
study of a single ascending dose (SAD) and a multiple ascending dose (MAD) of the oral …

Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in
phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for …

Long-term anticoagulation treatment with warfarin has been associated with a number of
limitations in clinical practice and there is a need for more convenient long-term …

Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in
a concentration-dependent manner. This review describes the extensive clinical …

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in
patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) …

This study determined the mass balance and pharmacokinetics of edoxaban in humans after
oral administration of [14C] edoxaban. After oral administration of 60 mg (as active moiety) of …

Aims To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
edoxaban, an oral direct factor Xa inhibitor, in healthy subjects switching from warfarin …

Edoxaban, a once‐daily, oral, direct factor Xa inhibitor, is approved for stroke prevention in
nonvalvular atrial fibrillation and venous thromboembolism treatment. This study examined …

Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical development for
the prevention of stroke in atrial fibrillation (AF). A phase II study was undertaken to evaluate …